mAb_name,category,arm,VH_sequence,VL_sequence,CDR_H3,CDR_L3,target_epitope
Trastuzumab,Reference,Single,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,SRWGGDGFYAMDY,QQHYTTPPT,HER2 Domain IV (557-603)
Pertuzumab,Reference,Single,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARDTTFYDYYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPYTFGQGTKVEIK,DTTFYDYYAMDY,QQYYIYPYT,HER2 Domain II (266-333)
Zanidatamab,Reference,Arm1 (Domain IV-like),EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,SRWGGDGFYAMDY,N/A,HER2 Domain II + Domain IV (Biparatopic)
Zanidatamab,Reference,Arm2 (Domain II-like),EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARDTTFYDYYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPYTFGQGTKVEIK,DTTFYDYYAMDY,N/A,HER2 Domain II + Domain IV (Biparatopic)
p95-mAb-001,Predicted,Single,EVQLVESGGGLVQPGGSLRLSCAASGFTIKSYAMHWVRQAPGKGLEWVAKIWPFGGATNYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPIWKFPDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSYLAWYQQKPGKAPKLLIYEASSRASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGACQPLTFGQGTKVEIK,DPIWKFPDY,QQGACQPLT,p95-HER2 Juxtamembrane (615-635)
p95-mAb-002,Predicted,Single,EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARMETPIWKFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFPDEEGTFGQGTKVEIK,METPIWKFDY,QQFPDEEGT,p95-HER2 Neo-epitope (611-625)
p95-mAb-003,Predicted,Single,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVASISGGGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARCTHSCVDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVDSYLNWYQQKPGKAPKLLIYDASNRATGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQDLDKGCTFGQGTKVEIK,CTHSCVDY,QQDLDKGCT,p95-HER2 Membrane-proximal (640-652)
p95-Bispecific-001,Predicted,Arm1 (p95-JM targeting),EVQLVESGGGLVQPGGSLRLSCAASGFTIKSYAMHWVRQAPGKGLEWVAKIWPFGGATNYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPIWKFPDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSYLAWYQQKPGKAPKLLIYEASSRASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGACQPLTFGQGTKVEIK,DPIWKFPDY,QQGACQPLT,p95-HER2 JM (615-635)
p95-Bispecific-001,Predicted,Arm2 (Domain IV targeting),EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,SRWGGDGFYAMDY,QQHYTTPPT,FL-HER2 Domain IV (557-603)
